At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 124 enrolled
Drug / intervention
PRM-151 +1 moredrug
Likely dose
PRM-151 2 milligramsfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Randomized, Double-Masked, Placebo-Controlled Study of PRM-151 in the Prevention of Postoperative Scarring in Glaucoma Patients Following Primary Trabeculectomy
In Brief
A Phase 2 clinical trial evaluating PRM-151 and Placebo for Glaucoma. Completed, enrolled 124 participants across 14 sites in 4 countries.
Detailed Summary
This study will assess the safety and tolerability of PRM-151 administered as a subconjunctival injection and explore the effect of PRM-151 on various correlates of the wound healing process that occurs in the eye after glaucoma filtration surgery.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsGlaucoma
CountriesBelgium, Czechia, Netherlands, United Kingdom
Collaborators--
Timeline
Phase 2CompletedFinished
20102011201220132014201520162017201820192020202120222023202420252026
First PostedFeb 2010
Enrollment StartJun 2010
Primary CompletionApr 2012
Study CompletionNov 2012
TodayJul 2026
First PostedFeb 8, 2010
Enrollment StartJun 14, 2010
Primary CompletionApr 30, 2012
Study CompletionNov 14, 2012
TodayJul 2, 2026
Enrollment to primary: 1.9 yearsPosted 16.4 years ago
Interventions
PRM-151drug
PRM-151 2 milligrams (mg) (0.1 mL volume) by subconjunctival injection Days 1 (immediately following trabeculectomy), 2, 3, 5 and 9
Placebodrug
Placebo solution (0.1 mL volume) by subconjunctival injection Days 1 (immediately following trabeculectomy), 2, 3, 5 and 9